Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study.
Ashina M, Mitsikostas DD, Amin FM, Kokturk P, Schankin CJ, Sahin G, Pozo-Rosich P, Dorman PJ, Nežádal T, Poole AC, Martins IP, Sumelahti ML, Ramirez Campos V, Ahn AH, Lyras L, Tassorelli C. Ashina M, et al. Among authors: ramirez campos v. Cephalalgia. 2023 Nov;43(11):3331024231214987. doi: 10.1177/03331024231214987. Cephalalgia. 2023. PMID: 37987641 Free article. Clinical Trial.
Numbers needed to treat or harm and likelihood of being helped versus harmed for fremanezumab in patients who had prior inadequate response to two to four classes of migraine preventive medications: A post hoc analysis.
Ashina M, Mitsikostas DD, Ramirez Campos V, Barash S, Ning X, Diener HC. Ashina M, et al. Among authors: ramirez campos v. Headache. 2023 Nov-Dec;63(10):1351-1358. doi: 10.1111/head.14651. Epub 2023 Nov 13. Headache. 2023. PMID: 37955395 Clinical Trial.
Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study.
Spierings ELH, Ning X, Ramirez Campos V, Cohen JM, Barash S, Buse DC. Spierings ELH, et al. Among authors: ramirez campos v. Headache. 2021 Oct;61(9):1376-1386. doi: 10.1111/head.14196. Epub 2021 Aug 10. Headache. 2021. PMID: 34374086 Free PMC article. Clinical Trial.
Clinical characteristics and patient-reported outcomes of chronic and episodic migraine patients at a US tertiary headache center: A retrospective observational study.
Ahmed Z, Honomichl R, Thompson SF, Cohen JM, Schuster A, Thompson NR, Lapin B, Udeh BL, Ramirez Campos V, Krasenbaum LJ, Katzan IL. Ahmed Z, et al. Among authors: ramirez campos v. Headache. 2023 Jul-Aug;63(7):908-916. doi: 10.1111/head.14527. Epub 2023 Jun 14. Headache. 2023. PMID: 37314065
Comment on: Gao B, Lu Q, Wan R, Wang Z, Yang Y, Chen Z, Wang Z. "Monthly versus quarterly fremanezumab for the prevention of migraine: a systemic review and meta-analysis from randomized controlled trials". Naunyn Schmiedebergs Arch Pharmacol. 2021 Apr;394(4):819-828. Epublished November 2020.
Barash S, Ramirez Campos V, Ning X, Driessen MT, Krasenbaum LJ, Carr K, Cohen JM. Barash S, et al. Among authors: ramirez campos v. Naunyn Schmiedebergs Arch Pharmacol. 2021 Nov;394(11):2343-2346. doi: 10.1007/s00210-021-02156-5. Epub 2021 Sep 28. Naunyn Schmiedebergs Arch Pharmacol. 2021. PMID: 34581836 Free PMC article.
Adverse Events Reported with Therapies Targeting the CGRP Pathway During the First 6 Months Post-launch: A Retrospective Analysis Using the FDA Adverse Events Reporting System.
Silberstein SD, Reshef S, Cohen JM, Gandhi S, Seminerio M, Ramirez Campos V, Kessler Y, Thompson SF, Blumenfeld A. Silberstein SD, et al. Among authors: ramirez campos v. Adv Ther. 2023 Feb;40(2):445-459. doi: 10.1007/s12325-022-02346-4. Epub 2022 Nov 9. Adv Ther. 2023. PMID: 36350532 Free PMC article.